Considerations for long-term use of proton-pump inhibitors

American Journal of Health-System Pharmacy

Volumn 55, Issue 21, 1998, Pages 2268-2279

  Garnett, William R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Achlorhydria; Dosage schedules; Drug interactions; Gastroesophageal reflux; Gastrointestinal drugs; Nutrition disorders; Peptic ulcer; Toxicity

Indexed keywords

CLARITHROMYCIN; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ABDOMINAL PAIN; ACHLORHYDRIA; BACTERIAL OVERGROWTH; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG SAFETY; DYSPEPSIA; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; VERTIGO;

EID: 0032212949     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.21.2268     Document Type: Review

References (166)

1. Wallmark B. Mechanism of action of omeprazole. Scand J Gastroenterol. 1986; 21(suppl):11-7.
2. Lampkin TA, Quellet D, Hak LJ et al. Omeprazole: a novel antisecretory agent for the treatment of acid-peptic disorders. DICP Ann Pharmacother. 1990; 24:393-402.
3. Prilosec package insert. Wayne, PA: Astra Merck; 1998 Jun.
4. Prevacid package insert. Deerfield, IL: TAP Pharmaceuticals; 1998 Jun.
5. Ekman L, Hansson E, Havu N et al. Toxicological studies on omeprazole. Scand J Gastroenterol. 1985; 20(suppl 108):53-69.
6. Joelson S, Joelson I-B, Lundborg P et al. Safety experience from long-term treatment with omeprazole. Digestion. 1992; 51(suppl 1):93-101.
7. Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther. 1993; 7(suppl 1):58-66.
8. Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med. 1988; 319:1707-15.
9. Walsh JH, Grossman MI. Gastrin. N Engl J Med. 1975; 292:1324-34.
10. Walsh JH. Role of gastrin as a trophic hormone. Digestion. 1990; 47(suppl 1):11-6.
11. Håkanson R, Blom H, Carlsson E et al. Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regul Pept. 1986; 13:225-33.
12. Dembinski AB, Johnson LR. Growth of pancreas and gastrointestinal mucosa in antrectomized and gastrin-treated rats. Endocrinology. 1979; 105:769-73.
13. Ahnen DJ, Bozdech J. Gastrin as a trophic hormone for the colon. In: Walsh JH, ed. Gastrin. New York: Raven; 1993: 301-6.
14. Brand SJ, Schmidt WE. Gastrointestinal hormones. In: Yamada T, Alpers DH, Powell DW et al., eds. Textbook of gastroenterology. 2nd ed. Philadelphia: J. B. Lippincott; 1995:25-71.
15. Bold RJ, Ishizuka J, Townsend CM Jr et al. Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B. Biochem Biophys Res Commun. 1994; 202:1222-6.
16. Imdahl A, Mantamadiotis T, Eggstein S et al. Expression of gastrin, gastrin/CCK-B and gastrin/CCK-C receptors in human colorectal carcinomas. J Cancer Res Clin Oncol. 1995; 121:661-6.
17. Baldwin GS. Antiproliferative gastrin/cholecystokinin receptor antagonists target the 78-kDa gastrin-binding protein. Proc Natl Acad Sci USA. 1994; 91:7593-7.
18. Johnson LR. The trophic action of gastrointestinal hormones. Gastroenterology. 1976; 70:278-88.
19. Simonsson M, Eriksson S, Håkanson R et al. Endocrine cells in the human oxyntic mucosa. A histochemical study. Scand J Gastroenterol. 1988; 23:1089-99.
20. Håkanson R, Böttcher G, Sundler F et al. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. Digestion. 1986; 35(suppl 1):23-41.
21. Håkanson R, Böttcher G, Ekblad E et al. Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies. Histochemistry. 1986; 86:5-17.
22. Lönroth H, Håkanson R, Lundell L et al. Histamine containing endocrine cells in the human stomach. Gut. 1990; 31:383-8.
23. Mak KM, Chang WWL. Pentagastrin stimulates epithelial cell proliferation in duodenal and colonic crypts in fasted rats. Gastroenterology. 1976; 71:1117-20.
24. Johnson LR, Lichtenberger LM, Copeland EM et al. Action of gastrin on gastrointestinal structure and function. Gastroenterology. 1975; 68:1184-92.
25. 15]-gastrin-17 in the rat. Gastroenterology. 1990; 98:33-8.
26. Sobhani I, Lehy T, Laurent-Puig P et al. Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology. 1993; 105:22-30.
27. Håkanson R, Sundler F. Proposed mechanism of induction of gastric carcinoids: the gastrin hypothesis. Eur J Clin Invest. 1990; 20(suppl 1):S65-71.
28. Modlin IM, Tang LH. The gastric enterochromaffin-like cell: an enigmatic cellular link. Gastroenterology. 1996; 111:783-810.
29. Havu N, Mattsson H, Ekman L et al. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion. 1990; 45:189-95.
30. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986; 35(suppl 1):42-55.
31. Mattsson H, Havu N, Bräutigam J et al. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology. 1991; 100:311-9.
32. Håkanson R, Larsson L-I, Liedberg G et al. Effects of antrectomy or porta-caval shunting on the histamine-storing endocrine-like cells in oxyntic mucosa of rat stomach. A fluorescence histochemical, electron microscopic and chemical study. J Physiol. 1976; 259:785-800.
33. Freston JW. Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion. 1992; 51(suppl 1):102-14.
34. Axelson J, Håkanson R, Rosengren E et al. Hypergastrinaemia induced by acid blockade evokes enterochromaffin-like (ECL) cell hyperplasia in chicken, hamster and guinea-pig stomach. Cell Tissue Res. 1988; 254:511-6.
35. Rindi G, Luinetti O, Cornaggia M et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993; 104:994-1006.
36. Solcia E, Rindi G, Fiocca R et al. Endocrine proliferation and carcinoids in hypergastrinemia. In: Walsh JH, ed. Gastrin. New York: Raven; 1993:361-71.
37. Solcia E, Fiocca R, Havu N et al. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion. 1992; 51(suppl 1):82-92.
38. Lamberts R, Creutzfeldt W, Strüber HG et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993; 104:1356-70.
39. Dent J, Yeomans ND, Mackinnon M et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut. 1994; 35:590-8.
40. Eissele R, Brunner G, Fischer B et al. Evaluation of enterochromaffin-like (ECL)-cell hyperplasia during long-term treatment with the proton pump inhibitor lansoprazole. Gastroenterology. 1993; 104:A74. Abstract.
41. Brunner G, Harke U. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther. 1994; 8(suppl 1):59-64.
42. Lee AK, deLellis RA, Blount M et al. Pituitary proliferative lesions in aging male Long-Evans rats. A model of mixed multiple endocrine neoplasia syndrome. Lab Invest. 1982; 47:595-602.
43. Hazell SL, Lee A, Brady L et al. Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J Infect Dis. 1986; 153:658-63.
44. Sipponen P, Hyvärinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol. 1993; 28(suppl 196):3-6.
45. Fontham ETH, Ruiz B, Perez A et al. Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol. 1995; 90:1094-101.
46. Genta RM, Hamner HW, Graham DY. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol. 1993; 24:577-83.
47. Kuipers EJ, Pena AS, van Kamp G et al. Seroconversion for Helicobacter pylori. Lancet. 1993; 342:328-31.
48. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65-9.
49. Hansson L-E, Nyrén O, Hsing AW et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med. 1996; 335:242-9.
50. Eidt S, Stolte M. The significance of Helicobacter pylori in relation to gastric cancer and lymphoma. Eur J Gastroenterol Hepatol. 1995; 7:318-21.
51. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994; 61:177-240.
52. Fiocca R, Villani L, Luinetti O et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat. 1992; 420:489-98.
53. Stolte M, Bethke B, Blum AL et al. Antacid treatment has a deleterious effect on the severity and activity of gastritis of the corpus mucosa. Ir J Med Sci. 1992; 161:6. Abstract.
54. Correa P. Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol. 1988; 83:504-9.
55. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992; 52:6735-40.
56. Sipponen P, Kekki M, Seppälä K et al. The relationships between chronic gastritis and gastric acid secretion. Aliment Pharmacol Ther. 1996; 10(suppl 1):103-18.
57. Sipponen P, Kosunen TU, Valle J et al. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol. 1992; 45:319-23.
58. Sipponen P, Kekki M, Happakoski J et al. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer. 1985; 35:173-7.
59. Kuipers EJ, Uyterlinde AM, Pena AS et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995; 345:1525-8.
60. Solcia E, Fiocca R, Luinetti O et al. Intestinal and diffuse gastric cancers arise in a different backgound of Helicobacter pylori gastritis through different gene involvement. Am J Surg Pathol. 1996; 20(suppl 1):S8-22.
61. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127-31.
62. Rothery GA, Day DW. Intestinal metaplasia in endoscopic biopsy specimens of gastric mucosa. J Clin Pathol. 1985; 38:613-21.
63. Solcia E, Villani L, Fiocca R et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol. 1994; 29(suppl 201):28-34.
64. Uemura N, Mukai T, Okamoto S et al. Helicobacter pylori eradication inhibits the growth of intestinal type of gastric cancer in initial stage. Gastroenterology. 1996; 110:A282. Abstract.
65. Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996; 334:1018-22.
66. Lundell L, Havu N, Andersson A et al. Gastritis development and acid suppression therapy revisited. Results of a randomized clinical study with long-term follow-up. Gastroenterology. 1997; 112:A28. Abstract.
67. Bank S, Blumstein M, Greenberg R et al. Is intermittent or spaced omeprazole dosing in the maintenance treatment of erosive esophagitis a therapeutic option? Results after 2-8 years of continuous therapy. Am J Gastroenterol. 1996; 91:1882. Abstract.
68. Goh KL, Boonyapisit S, Lai K-H et al. Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: a randomized double-blind, placebo-controlled study. J Gastroenterol Hepatol. 1995; 10:92-7.
69. Cadiot G, Vissuzaine C, Pospai D et al. Influence des traitements prolongés par inhibiteurs de la pompe à protons sur la gastrinémie et la muqueuse fundique. Résultats préliminaires. Gastroenterol Clin Biol. 1995; 19:811-7.
70. Diebold MD, Richardson S, Zeitoun P et al. Influence of the degree of severity of fundic gastritis on serum gastrin concentration and ECL cell density in controls and during prolonged treatment with antisecretory drugs. Gastroenterology. 1995; 108:A83. Abstract.
71. Maaroos H-I, Salupere V, Uibo R et al. Seven-year follow-up study of chronic gastritis in gastric ulcer patients. Scand J Gastroenterol. 1985; 20:198-204.
72. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994; 121:161-7.
73. Watson SA, Clifford T, Sykes RE et al. Gastrin sensitivity of primary human colorectal cancer: the effect of gastrin receptor antagonism. Eur J Cancer. 1995; 31A:2086-92.
74. Chu M, Nielsen FC, Franzén L et al. Effect of endogenous hypergastrinemia on gastrin receptor expressing human colon carcinoma transplanted to athymic rats. Gastroenterology. 1995; 109:1415-20.
75. McGregor DB, Jones RD, Karlin DA et al. Trophic effects of gastrin on colorectal neoplasms in the rat. Ann Surg. 1982; 195:219-23.
76. Karlin DA, McBath M, Jones RD et al. Hypergastrinemia and colorectal carcinogenesis in the rat. Cancer Lett. 1985; 29:73-8.
77. Winsett OE, Townsend CM Jr, Glass EJ et al. Gastrin stimulates growth of colon cancer. Surgery. 1986; 99:302-7.
78. Smith JP, Solomon TE. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology. 1988; 95:1541-8.
79. D'Agostino L, Pignata S, Tritto G et al. Hypergastrinemia in rats with azoxymethane-induced colon cancers. Int J Cancer. 1995; 61:223-6.
80. Watson SA, Durrant LG, Crosbie JD et al. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int J Cancer. 1989; 43:692-6.
81. Smith JP, Wood JG, Solomon TE. Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci. 1989; 34:171-4.
82. Seitz J-F, Giovannini M, Gouvernet J et al. Elevated serum gastrin levels in patients with colorectal neoplasia. J Clin Gastroenterol. 1991; 13:541-5.
83. Charnley RM, Thomas WM, Stanley J et al. Serum gastrin concentrations in colorectal cancer patients. Ann R Coll Surg Engl. 1992; 74:138-41.
84. Suzuki H, Matsumoto K, Terashima H. Serum levels of gastrin in patients with colorectal neoplasia. Dis Colon Rectum. 1988; 31:716-7.
85. Elewaut A, Vanderstraeten E. Serum gastrin levels and colorectal neoplasia. Gastroenterology. 1995; 108:618-9.
86. Kikendall JW, Glass AR, Sobin LH et al. Serum gastrin is not higher in subjects with colonic neoplasia. Am J Gastroenterol. 1992; 87:1394-7.
87. Orbuch M, Venzon DJ, Lubensky IA et al. Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Dig Dis Sci. 1996; 41:604-13.
88. Yapp R, Modlin IM, Kumar RR et al. Gastrin and colorectal cancer. Evidence against an association. Dig Dis Sci. 1992; 37:481-4.
89. Penman ID, El-Omar E, Ardill JES et al. Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology. 1994; 106:1263-70.
90. Wilder-Smith CH, Spirig C, Krech T et al. Bactericidal factors in gastric juice. Eur J Gastroenterol Hepatol. 1992; 4:885-91.
91. Modlin IM, Goldenring JR, Lawton GP et al. Aspects of the theoretical basis and clinical relevance of low acid states. Am J Gastroenterol. 1994; 89:308-18.
92. Sharma BK, Santana IA, Wood EC et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J. 1984; 289:717-9.
93. Verdu E, Viani F, Armstrong D et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994; 35:455-60.
94. Fried M, Siegrist H, Frei R et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut. 1994; 35:23-6.
95. Thorens J, Froehlich F, Schwizer W et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996; 39:54-9.
96. Verdu EF, Fraser R, Armstrong D et al. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol. 1994; 29:1065-9.
97. Ramdani A, Paul G, Ruszniewski P et al. Comparative efficiency of lansoprazole and omeprazole on 24-hour intragastric pH measurement in 9 cases of Zollinger-Ellison syndrome. Gastroenterology. 1992; 102:A151. Abstract.
98. Ruddell WSJ, Bone ES, Hill MJ et al. Gastric-juice nitrite. A risk factor for cancer in the hypochlorhydric stomach? Lancet. 1976; 2:1037-9.
99. Stockbrugger RW, Cotton PB, Eugenides N et al. Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment. Gut. 1982; 23:1048-54.
100. Saltzman JR, Kowdley KV, Pedrosa MC et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 1994; 106:615-23.
101. Serfaty-Lacrosniere C, Wood RJ, Voytko D et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995; 14:364-8.
102. 12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992; 14:288-92.
103. Steinberg WM, King CE, Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci. 1980; 25:188-91.
104. Belaiche J, Cattan D, Zittoun J et al. Effect of ranitidine on cobalamin absorption. Dig Dis Sci. 1983; 28:667-8.
105. Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther. 1992; 6:399-406.
106. Kittang E, Aadland E, Schjønsby H. Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man. Gut. 1985; 26:594-8.
107. 12). Ann Intern Med. 1994; 120:211-5.
108. Festen H, Klinkenberg-Knol E, Kuipers E et al. Cobalamin absorption during omeprazole treatment: short and long-term studies. Gastroenterology. 1993; 104:A77. Abstract.
109. 12 absorption. J Am Coll Nutr. 1994; 13:584-91.
110. 12 levels in patients with Zollinger-Ellison syndrome. Gastroenterology. 1995; 108:A226. Abstract.
111. 12 serum levels. Gastroenterology. 1994; 106:A140. Abstract.
112. Andersson T, Andrén K, Cederberg C et al. Bioavailability of omeprazole as enteric coated (EC) granules in conjunction with food on the first and seventh days of treatment. Drug Invest. 1990; 2:184-8.
113. Delhotal-Landes B, Cournot A, Vermerie N et al. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet. 1994; 111:315-20.
114. Bergstrand R, Grind M, Nyberg G et al. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest. 1995; 9:67-71.
115. Benet LZ, Zech K. Pharmacokinetics - a relevant factor for the choice of a drug? Aliment Pharmacol Ther. 1994; 8(suppl 1):25-32.
116. Gerloff J, Mignot A, Barth H et al. The absolute bioavailability of lansoprazole. Naunyn Schmiedebergs Arch Pharmacol. 1994; 349(suppl):R135. Abstract.
117. Regårdh C-G, Gabrielsson M, Hoffman K-J et al. Pharmacokinetics and metabolism of omeprazole in animals and man - an overview. Scand J Gastroenterol. 1985; 20(suppl 108):79-94.
118. Huber R, Kohl B, Sachs G et al. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther. 1995; 9:363-78.
119. Regårdh CG, Andersson T, Lagerström PO et al. The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses. Ther Drug Monit. 1990; 12:163-72.
120. Tateno M, Nakamura N. Phase I study of lansoprazole (AG-1749) antiulcer agent - capsule form. Rinsho Iyaku. 1991; 7:51-62.
121. Steinijans VW, Huber R, Hartmann M et al. Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther. 1994; 32:385-99.
122. Andersson T, Miners JO, Veronese ME et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol. 1993; 36:521-30.
123. Chiba K, Kobayashi K, Manabe K et al. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther. 1993; 266:52-9.
124. Andersson T, Miners JO, Veronese ME et al. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol. 1994; 37:597-604.
125. Curi-Pedrosa R, Pichard L, Bonfils C et al. Major implication of cytochrome P4503A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. Br J Clin Pharmacol. 1993; 36:156P.
126. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther. 1994; 8(suppl 1):33-8.
127. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996; 31:1-21.
128. Piscitelli SC, Goss TF, Wilton JH et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991; 35:1765-71.
129. Andersson T, Andrén K, Cederberg C et al. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol. 1990; 39:51-4.
130. Andersson T, Cederberg C, Edvardsson G et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990; 47:79-85.
131. Lefebvre RA, Flouvat B, Karolac-Tamisier S et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther. 1992; 52:458-63.
132. Gugler R, Hartmann M, Rudi J et al. Lack of interaction of pantoprazole and diazepam in man. Gastroenterology. 1992; 102:A77. Abstract.
133. Unge P, Svedberg L-E, Nordgren A et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992; 34:509-12.
134. Cavanaugh JH, Winters EP, Cohen A et al. Lack of effect of lansoprazole on steady state warfarin metabolism. Gastroenterology. 1991; 100 (suppl):A40. Abstract.
135. Duursema L, Müller FO, Schall R et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol. 1995; 39:700-3.
136. Andersson T, Lagerström P-O, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit. 1990; 12:329-33.
137. Karol MD, Mukherji D, Cavanaugh JH. Lack of effect of concomitant multi-dose lansoprazole on single-dose phenytoin pharmacokinetics in subjects. Gastroenterology. 1994; 106:A103. Abstract.
138. Blohmé I, Idström J-P, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol. 1993; 35:156-60.
139. Galbraith RA, Michnovicz JJ. Omeprazole fails to alter the cytochrome P450-dependent 2-hydroxylation of estradiol in male volunteers. Pharmacology. 1993; 47:8-12.
140. Noble DW, Bannister J, Lamont M et al. The effect of oral omeprazole on the disposition of lignocaine. Anaesthesia. 1994; 49:497-500.
141. Soons PA, van den Berg G, Danhof M et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 1992; 42:319-24.
142. Ching MS, Elliot SL, Stead CK et al. Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. Aliment Pharmacol Ther. 1991; 5:523-31.
143. Rost KL, Brösicke H, Heinemeyer G et al. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology. 1994; 20:1204-12.
144. Fuchs W, Sennewald R, Klotz U. Lansoprazole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol. 1994; 38:376-80.
145. Reill L, Erhardt F, Fischer R et al. Effect of oral pantoprazole on 24-hour intragastric pH, serum gastrin profile and drug metabolising enzyme activity in man - a placebo-controlled comparison with ranitidine. Gut. 1993; 34(suppl):63. Abstract.
146. Cavanaugh JH, Locke C, Karol M. Lack of interaction of lansoprazole or omeprazole with prednisone. Am J Gastroenterol. 1993; 88:1589. Abstract.
147. Middle MV, Müller FO, Schall R et al. Effect of pantoprazole on ovulation suppression by a low-dose hormonal contraceptive. Clin Drug Invest. 1995; 9:54-6.
148. Henry D, Brent P, Whyte I et al. Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol. 1987; 33:369-73.
149. Cavanaugh JH, Schneck DW, Mukherji D et al. Lack of effect of concomitant lansoprazole on single-dose propranolol pharmacokinetics and pharmacodynamics. Gastroenterology. 1994; 106:A4. Abstract.
150. Nousbaum JB, Berthou F, Carlhant D et al. Four-week treatment with omeprazole increases the metabolism of caffeine. Am J Gastroenterol. 1994; 89:371-5.
151. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther. 1994; 55:402-11.
152. Andersson T, Bergstrand R, Cederberg C et al. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology. 1991; 101:943-7.
153. Andersson T, Lundborg P, Regårdh CG. Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur J Clin Pharmacol. 1991; 40:61-5.
154. Xiaodong S, Gatti G, Bartoli A et al. Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers. Ther Drug Monit. 1994; 16:248-50.
155. 2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther. 1987; 33:133-7.
156. Taburet AM, Geneve J, Bocquentin M et al. Theophylline steady state pharmacokinetics is not altered by omeprazole. Eur J Clin Pharmacol. 1992; 42:343-5.
157. Oosterhuis B, Jonkman JHG, Andersson T et al. No influence of single intravenous doses of omeprazole on theophylline elimination kinetics. J Clin Pharmacol. 1992; 32:470-5.
158. Granneman G, Winters EP, Locke CS et al. Lack of effect of concomitant lansoprazole on steady-state theophylline pharmacokinetics. Gastroenterology. 1991; 100:A75. Abstract.
159. Roine R, Hernández-Muñoz R, Baraona E et al. Effect of omeprazole on gastric first-pass metabolism of ethanol. Dig Dis Sci. 1992; 37:891-6.
160. Oosterhuis B, Jonkman JHG, Andersson T et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991; 32:569-72.
161. Hartmann M, Huber R, Bliesath H et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. In: Management of acid-related diseases: focus on pantoprazole. Congress abstracts. Berlin, Germany: Charite; 1993:34-5.
162. Cohen AF, Kroon R, Schoemaker R et al. Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med. 1991; 115:540-5.
163. Soons PA, van den Berg G, Danhof M et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol. 1992; 42:319-24.
164. Bliesath H, Huber R, Hartmann M et al. Pantoprazole does not influence the steady-state pharmacokinetics of nifedipine. Gastroenterology. 1994; 106(suppl):A55. Abstract.
165. Paulsen O, Hoglund P, Walder M. No effect of omeprazole-induced hypoacidity on the bioavailability of amoxycillin or bacampicillin. Scand J Infect Dis. 1989; 21:219-23.
166. Haraguchi Y, Kitani M, Morisako K et al. Effect of lansoprazole on iron absorption. Jpn Pharmacol Ther. 1994; 22469-72.